Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2006-05-23
2006-05-23
Badio, Barbara P. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S176000, C514S182000, C540S109000, C540S114000, C540S120000, C552S609000
Reexamination Certificate
active
07049305
ABSTRACT:
This invention is directed to compounds that provide for sustained systemic concentrations of therapeutic or prophylactic agents following administration to animals. This invention is also directed to pharmaceutical compositions including and methods using such compounds.
REFERENCES:
patent: 4024175 (1977-05-01), Satzinger et al.
patent: 5462933 (1995-10-01), Kramer et al.
patent: 5541348 (1996-07-01), Arya et al.
patent: 5563175 (1996-10-01), Silverman et al.
patent: 5646272 (1997-07-01), Kramer et al.
patent: 5668126 (1997-09-01), Kramer et al.
patent: 6020370 (2000-02-01), Horwell et al.
patent: 6028214 (2000-02-01), Silverman et al.
patent: 6103932 (2000-08-01), Horwell et al.
patent: 6117906 (2000-09-01), Silverman et al.
patent: 0 272 462 (1988-06-01), None
patent: WO 92/09560 (1992-06-01), None
patent: WO 93/23383 (1993-11-01), None
patent: WO 97/29101 (1997-08-01), None
patent: WO 97/33858 (1997-09-01), None
patent: WO 97/33859 (1997-09-01), None
patent: WO 98/17627 (1998-04-01), None
patent: WO 99/08671 (1999-02-01), None
patent: WO 99/21824 (1999-05-01), None
patent: WO 99/31057 (1999-06-01), None
patent: WO 99/31074 (1999-06-01), None
patent: WO 99/31075 (1999-06-01), None
patent: WO 99/61424 (1999-12-01), None
patent: WO 00/15611 (2000-03-01), None
patent: WO 00/23067 (2000-04-01), None
patent: WO 00/31020 (2000-06-01), None
patent: WO 00/50027 (2000-08-01), None
patent: WO 01/20331 (2001-03-01), None
Batta et al., “Characterization of Sarcosylsarcoursodeoxycholic acid formed during the synthesis of sarcoursodeoxycholic acid”,Journal of Lipid Research,1989, vol. 30, No. 5, pp. 771-774, see the entire article, especially Table I, compounds 3 and 5.
Huijghbaert et al., “Pancreatic Carboxypeptidase Hydrolysis of Bile Acid-Amino Acid Conjugates: Selective Resistance of Glycine and Taurine Amidates”,Gastroenterology,1986, vol. 90, No. 2, pp. 306-315, see the entire article, especially p. 307, Synthetic bile acid conjugates.
International Search Report mailed Mar. 14, 2003.
Ballatore et al., “Synthesis and Spectroscopic Analysis of Modified Bile Salts,”Steroids,vol. 41(2), pp. 197-206, 1983.
Nair et al., “Electron Impact Ionization Mass Spectra of Lithocholyl Amides: Evidences for a C(20) to C(23) Rearrangement Involving the Loss of a C4H9 Fragment,”Organic Mass Spectrometry,vol. 29(7), pp. 335-341, 1994.
Swaan et al., “Use of the Intestinal and Hepatic Bile Acid Transporters for Drug Delivery,”Adv. Drug Delivery Rev.,vol. 20, pp. 59-82, 1996.
S.A. Abidi,Gastroenterology,vol. 113, pp. 332-340, 1997.
Barringhaus et al., “Substrate Specificity of the Ileal and Hepatic Na+/bile acid Co-transporters of the Rabbit: II. A reliable . . . ,”J. Lipid Res.,vol. 40, pp. 2158-2168, 1999.
Bryans et al., “3-Substituted GABA Analogs With Central Nervous System Activity: a Review,”Med. Res. Rev.,vol. 19, pp. 149-177, 1999.
H. Bundgaard, inDesign of Prodrugs(Bundgaard, H. Ed.), Elsevier Science B.V., pp. 1-92, 1985.
Dieck et al.,GLIA,vol. 25, pp. 10-20, 1999.
N.F.H. No, “Utilizing Bile Acid Carrier Mechanisms to Enhance Liver and Small Intestine Absorption,”Ann. N.Y. Acad. Sci.,vol. 507, pp. 315-329, 1987.
Jezyk et al., “Transport of Pregabalin in Rat Intestin anc Caco-2 Monolayers,”Pharm. Res.,vol. 16, pp. 519-526, 1999.
Kagedahl et al., “Use of Intestinal Bile Acid Transporter for the Uptake of Cholic Acid Conjugates with HIV-1 Protease Inhibitory Activity,”Pharm. Res.,vol. 14, pp. 176-180, 1997.
D.C. Kim, “Evaluation of bile acid transporter in enhancing intestinal permeability of rennin-inhibitory peptides,”J. Drug Targeting,vol. 1, pp. 347-359, 1993.
Kramer et al., “Liver-specific drug targeting by coupling to bile acids,”J. Biol. Chem.,vol. 267, pp. 18598-18604, 1992.
Kramer et al., “Intestinal absorption of peptides by coupling to bile acids,”J. Biol. Chem.,vol. 269, pp. 10621-10627, 1994.
Kramer et al., “Bile acid derived HMG-CoA reductase inhibitors,”Biochem, Biophys. Acta.,vol. 1227, pp. 137-154, 1994.
Kramer et al., “Substrate specificity of the ileal and hepatic Na+/bile acid co-transporters of the rabbit I. transport studies with membrane vesicles and cell lines expressing the cloned transporters,”J. Lipid Res.,vol. 40, pp. 1604-1617, 1999.
Kullak-Ublick et al.,Hepatobiliary transport, J Hepatology,vol. 32 (Suppl. 1), pp. 3-18, 2000.
Leibach et al.,Ann. Rev. Nutr.,vol. 16, pp. 99-119, 1996.
Mills et al., “Ileal absorption of tyrosine-conjugated bile acids in Wistar rats,”Biochem. Biophys. Acta,vol. 926, pp. 154-159, 1987.
M.A. Navia, “Design principles for orally bioavailable drugs,”Drug Discovery Today,vol. 1, pp. 179-189, 1996.
Petzinger et al., “Hepatobiliary transport of hepatic 3-hydro-3-methylglutaryl coenzyme A reductase inhibitors conjugated with bile acids,”Hepatology,vol. 22, pp. 1801-1811, 1995.
Swaan et al., “Enhanced transepithelial transport of peptides by conjugation to cholic acid,”Bioconj. Chem.,vol. 8, pp. 520-525, 1997.
Tsuji et al., “Carrieri-mediated intestinal transport of drugs,”Pharm. Res.,vol. 13, pp. 963-977, 1996.
Wong et al.,Am. J. Physiol.,vol. 275, pp. C967-C975, 1998.
Cundy Kenneth C.
Gallop Mark A.
Zhou Cindy X.
Badio Barbara P.
Buchanan & Ingersoll PC
XenoPort, Inc.
LandOfFree
Bile-acid conjugates providing for sustained systemic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bile-acid conjugates providing for sustained systemic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bile-acid conjugates providing for sustained systemic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3540378